Frequently Asked Questions
32. Are there new studies under way to try and reduce a woman's chance of getting breast cancer?
Research shows women with early-stage breast cancer who took the drug letrozole, an aromatase inhibitor, after they completed five years of tamoxifen therapy significantly reduced their risk of breast cancer recurrence.
Also, other research found a test that can predict both the risk of breast cancer recurrence and who is most likely to benefit from chemotherapy such as letrozole.
Another study, known as TAILORx, was launched by the National Cancer Institute to examine whether genes that are frequently associated with risk of recurrence for women with early-stage breast cancer can be used to assign patients to the most appropriate and effective treatment.